BCRX vs. NK, NVAX, SRRK, CGEM, AUTL, IMTX, PROK, FDMT, RLAY, and VIR
Should you be buying BioCryst Pharmaceuticals stock or one of its competitors? The main competitors of BioCryst Pharmaceuticals include NantKwest (NK), Novavax (NVAX), Scholar Rock (SRRK), Cullinan Oncology (CGEM), Autolus Therapeutics (AUTL), Immatics (IMTX), ProKidney (PROK), 4D Molecular Therapeutics (FDMT), Relay Therapeutics (RLAY), and Vir Biotechnology (VIR). These companies are all part of the "medical" sector.
NantKwest (NASDAQ:NK) and BioCryst Pharmaceuticals (NASDAQ:BCRX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, community ranking, risk, analyst recommendations, media sentiment, earnings, valuation, profitability and institutional ownership.
9.4% of NantKwest shares are owned by institutional investors. Comparatively, 85.9% of BioCryst Pharmaceuticals shares are owned by institutional investors. 71.7% of NantKwest shares are owned by insiders. Comparatively, 4.4% of BioCryst Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
In the previous week, BioCryst Pharmaceuticals had 16 more articles in the media than NantKwest. MarketBeat recorded 16 mentions for BioCryst Pharmaceuticals and 0 mentions for NantKwest. NantKwest's average media sentiment score of 1.11 beat BioCryst Pharmaceuticals' score of 0.00 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the news media.
NantKwest has a beta of 2.61, meaning that its share price is 161% more volatile than the S&P 500. Comparatively, BioCryst Pharmaceuticals has a beta of 1.96, meaning that its share price is 96% more volatile than the S&P 500.
BioCryst Pharmaceuticals received 204 more outperform votes than NantKwest when rated by MarketBeat users. Likewise, 66.43% of users gave BioCryst Pharmaceuticals an outperform vote while only 53.42% of users gave NantKwest an outperform vote.
NantKwest has higher earnings, but lower revenue than BioCryst Pharmaceuticals. NantKwest is trading at a lower price-to-earnings ratio than BioCryst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
BioCryst Pharmaceuticals has a consensus target price of $14.00, suggesting a potential upside of 122.93%. Given NantKwest's higher possible upside, analysts clearly believe BioCryst Pharmaceuticals is more favorable than NantKwest.
BioCryst Pharmaceuticals has a net margin of -58.69% compared to BioCryst Pharmaceuticals' net margin of -76,658.58%. NantKwest's return on equity of 0.00% beat BioCryst Pharmaceuticals' return on equity.
Summary
BioCryst Pharmaceuticals beats NantKwest on 12 of the 17 factors compared between the two stocks.
Get BioCryst Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for BCRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BCRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BioCryst Pharmaceuticals Competitors List
Related Companies and Tools
